MediLink Therapeutics

MediLink Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for oncology. Founded in July 2020 and headquartered in Suzhou, Jiangsu, China, the company maintains additional R&D sites in Shanghai, China, and Boston, United States, along with other international presence.

MediLink owns the proprietary TMALIN® (Tumor Microenvironment Activable LINker-payload) platform technology, which supports the generation of homogeneous, high drug-to-antibody ratio ADCs featuring a dual-release mechanism for payload activation both extracellularly in the tumor microenvironment and intracellularly in lysosomes. This enables improved therapeutic windows for solid tumor treatments. The pipeline includes multiple clinical-stage candidates such as YL201 (tambotatug pelitecan or Tam-Peli), a B7-H3-targeted ADC that has advanced to Phase III trials in China for relapsed small-cell lung cancer and nasopharyngeal carcinoma, with NDA filings in China.

The company has secured major collaborations, including an exclusive licensing agreement with Roche for YL201 development and commercialization outside mainland China, Hong Kong, and Macau; partnerships with BioNTech for HER3 and multi-target ADCs; and deals with Zai Lab and others. As a privately held, venture capital-backed firm, MediLink emphasizes innovative conjugate technologies to address unmet needs in cancer treatment and has positioned itself as a key player in the global ADC space through clinical progress and strategic alliances.